The FDA approval of Eli Lilly's GLP-1 pill Foundayo comes nearly three months after Novo Nordisk's oral version of Wegovy hit ...

Eli Lilly’s once-daily Foundayo is the second obesity pill to receive FDA approval. It will compete with Novo Nordisk’s pill ...

Federal regulators on Wednesday approved Eli Lilly’s new weight-loss pill, a second daily oral medication to treat obesity ...

Eli Lilly’s obesity pill was approved by the FDA, setting it up for fierce competition against Novo Nordisk’s new Wegovy pill ...

"By working with Eli Lilly to make the KwikPen accessible on Ro's platform, we're continuing to help patients access the latest treatments, in the most innovative form factors, at the lowest possible ...

Foundayo, a once-daily oral GLP-1 medication approved for obesity and weight-related issues, ranges in cost from $25 to $349 ...

Demand for these drugs is high, and analysts predict the market will reach nearly $100 billion by the end of the decade. And ...

GLP-1 therapy Zepbound has become the biggest weight loss drug since its introduction, outpacing Novo Nordisk’s (NYSE:NVO) ...

If you are interested in buying Eli Lilly (NYSE: LLY) today, it is most likely because of the success of the company's GLP-1 ...

Eli Lilly and Company (NYSE:LLY) is one of the best forever stocks to buy now. On March 16, Eli Lilly and Company (NYSE:LLY) announced that its weight-loss drug Zepbound will be available for self-pay ...

Ro said it will offer a "complete end-to-end" experience on a single platform and app, allowing eligible patients to receive a diagnosis and a prescription for Zepbound and have vials of the drug ...

The U.S. Food and Drug Administration has approved Eli Lilly’s new weight-loss GLP-1 pill, orforglipron, which will be sold ...